Increasing resistance to current antibiotics is a growing public health threat. Creative alternatives to antibiotics are needed to meet this challenge. ioGenetics is developing novel first/best-in-class anti-infectives called “DBAF” (Directed Biocide® antibody fusions) to treat difficult infections such as MRSA and Strep. pneumoniae. DBAF are an alternate approach, using targeted delivery to cause lethal damage to microorganisms. The technology platform uses unique rational design based on uTOPE™ immunoinformatic analysis and a proven manufacturing technology, Rpex™, to discover, design, and produce products. Lead products include DBAF for Staphylococcus aureus (including MRSA) and Cryptosporidium.